-
Je něco špatně v tomto záznamu ?
Role of substance P in the cardiovascular system
E. Mistrova, P. Kruzliak, M. Chottova Dvorakova,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, přehledy
- MeSH
- antagonisté neurokininových receptorů typu 1 farmakologie MeSH
- ischemická choroba srdeční patofyziologie MeSH
- ischemie mozku patofyziologie MeSH
- kardiovaskulární fyziologické jevy * MeSH
- lidé MeSH
- mozek fyziologie MeSH
- nemoci srdce patofyziologie MeSH
- receptory neurokininu-1 fyziologie MeSH
- signální transdukce MeSH
- substance P biosyntéza metabolismus fyziologie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
This article provides an overview of the structure and function of substance P signalling system and its involvement in the cardiovascular regulation. Substance P is an undecapeptide originating from TAC1 gen and belonging to the tachykinin family. The biological actions of substance P are mainly mediated through neurokinin receptor 1 since substance P is the ligand with the highest affinity to neurokinin receptor 1. Substance P is widely distributed within the central and peripheral nervous systems as well as in the cardiovascular system. Substance P is involved in the regulation of heart frequency, blood pressure and in the stretching of vessels. Substance P plays an important role in ischemia and reperfusion and cardiovascular response to stress. Additionally, it has been also implicated in angiogenesis, pain transmission and inflammation. The substance P/neurokinin receptor 1 receptor system is involved in the molecular bases of many human pathological processes. Antagonists of neurokinin receptor 1 receptor could provide clinical solutions for a variety of diseases. Neurokinin receptor 1 antagonists are already used in the prevention of chemotherapy induced nausea and vomiting.
Biomedical Center Faculty of Medicine in Pilsen Charles University Prague Pilsen Czech Republic
Department of Internal Medicine Faculty of Medicine Masaryk University Brno Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17014179
- 003
- CZ-PrNML
- 005
- 20170426114018.0
- 007
- ta
- 008
- 170413s2016 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.npep.2015.12.005 $2 doi
- 035 __
- $a (PubMed)26706184
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Mistrova, Eliska $u Department of Physiology, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic; Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
- 245 10
- $a Role of substance P in the cardiovascular system / $c E. Mistrova, P. Kruzliak, M. Chottova Dvorakova,
- 520 9_
- $a This article provides an overview of the structure and function of substance P signalling system and its involvement in the cardiovascular regulation. Substance P is an undecapeptide originating from TAC1 gen and belonging to the tachykinin family. The biological actions of substance P are mainly mediated through neurokinin receptor 1 since substance P is the ligand with the highest affinity to neurokinin receptor 1. Substance P is widely distributed within the central and peripheral nervous systems as well as in the cardiovascular system. Substance P is involved in the regulation of heart frequency, blood pressure and in the stretching of vessels. Substance P plays an important role in ischemia and reperfusion and cardiovascular response to stress. Additionally, it has been also implicated in angiogenesis, pain transmission and inflammation. The substance P/neurokinin receptor 1 receptor system is involved in the molecular bases of many human pathological processes. Antagonists of neurokinin receptor 1 receptor could provide clinical solutions for a variety of diseases. Neurokinin receptor 1 antagonists are already used in the prevention of chemotherapy induced nausea and vomiting.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a mozek $x fyziologie $7 D001921
- 650 _2
- $a ischemie mozku $x patofyziologie $7 D002545
- 650 12
- $a kardiovaskulární fyziologické jevy $7 D002320
- 650 _2
- $a nemoci srdce $x patofyziologie $7 D006331
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ischemická choroba srdeční $x patofyziologie $7 D017202
- 650 _2
- $a antagonisté neurokininových receptorů typu 1 $x farmakologie $7 D064729
- 650 _2
- $a receptory neurokininu-1 $x fyziologie $7 D018040
- 650 _2
- $a signální transdukce $7 D015398
- 650 _2
- $a substance P $x biosyntéza $x metabolismus $x fyziologie $7 D013373
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Kruzliak, Peter $u Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic; 2(nd) Department of Internal Medicine, Faculty of Medicine, Masaryk University, Brno, Czech Republic. Electronic address: kruzliakpeter@gmail.com.
- 700 1_
- $a Chottova Dvorakova, Magdalena $u Department of Physiology, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic; Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
- 773 0_
- $w MED00005283 $t Neuropeptides $x 1532-2785 $g Roč. 58, č. - (2016), s. 41-51
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26706184 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170413 $b ABA008
- 991 __
- $a 20170426114337 $b ABA008
- 999 __
- $a ok $b bmc $g 1200644 $s 974957
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 58 $c - $d 41-51 $e 20151208 $i 1532-2785 $m Neuropeptides $n Neuropeptides $x MED00005283
- LZP __
- $a Pubmed-20170413
